The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • E-health company G Medical (GMV) has gained approval to join a U.S. over-the-counter market
  • The company is now tradable on the OTCQB under the code GMMVF
  • G Medical says it is looking to attract American individual and institutional investors
  • It plans to launch a shareholder engagement program in the U.S. soon
  • G Medical’s share price is up 12.12 per cent at midday trade
  • Shares in the company are now trading for 18 cents each

E-health company G Medical (GMV) has told shareholders it received U.S. approval to join over-the-counter market OTCQB. Company shares can now be traded under the code GMMVF.

On entering the American market, the company will have access to individual and institutional investors across the country.

G Medical detailed this will give it improved access to as its products gain popularity in the U.S. Additionally, it is expected to generate more growth opportunities.

“The company’s product suite is continuing to gain traction with medical organisations and healthcare professionals in the United States,” G Medical’s CEO Dr Yacov Geva said.

A medical smartphone case and a smart patch are two of the group’s popular products.

Dr Yacov outlined in today’s release the company is looking to begin securing American investors as it broadens its footprint in the country.

“An active shareholder engagement program is planned in the USA to ensure out investment attractions and growth prospects are highlighted amongst new investors,” he added.

After announcing the approval to the Australian market, G Medical’s share price is up 12.12 per cent at midday trade.

Shares in the company are now trading for 18 cents each.

GMV by the numbers
More From The Market Online
Metal detector

They say you should sell shovels in a gold rush. Codan’s got a smarter idea

Codan has notched gains just south of +20% on Friday, coming out of the blue as…
Australian currency cash

Mesoblast back to record highs as Ryoncil sales jump 60% QoQ to US$35M

Mesoblast is back onto investors' radars with good tidings from its sale of Ryoncil, with that…
Image of the human circulatory system

Health tech nanocap Hydrix pops +80% on deal with NYSE-listed Picard Medical

Hydrix came out of left field on Thursday, posting gains just south of +80% after the…
AI image of a lung cross section

4DX up another 15% on new demo delivery; now boasting $2.5B cap & no revenue

4DMedical has climbed to a lofty valuation just short of $4.80 on Wednesday, bringing the biotech…